Phase II Study With ITF2984 in Acromegalic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Acromegaly
Interventions
DRUG

Octreotide

octreotide 100 mcg sc t.i.d. for 4 weeks

DRUG

ITF2984 500 mcg

ITF2984 500 mcg sc b.i.d for 4 weeks

DRUG

ITF2984 1000 mcg

ITF2984 1000 mcg sc b.i.d for 4 weeks

DRUG

ITF2984 2000 mcg

ITF2984 2000 mcg sc b.i.d for 4 weeks

Trial Locations (26)

Unknown

St. Anne University Hospital, Brno

University Hospital Hradec Kralove, Hradec Králové

Université Hôpital Bicêtre, Le Kremlin-Bicêtre

Hôpital de la TIMONE, Marseille

Az MH Honvédkórház, Budapest

Semmelweis University, Budapest

University of Pecs, Pécs

University of Szeged, Szeged

Presidio Ospedaliero di Montichiari, Brescia

Policlinico G. Martino, Messina

Fondazione Policlinico IRCCS, Milan

IRCCS Ospedale San Raffaele, Milan

Università Federico II, Napoli

Università di Pisa, Pisa

San Giovanni Battista Molinette, Torino

Leiden University Medical Center, Leiden

Erasmus Medisch Centrum, Rotterdam

University Children's Hospital of Cracow, Krakow

Klinika Endokrynologii Centrum Medycznego Kształcenia Podyplomowego, Warsaw

Samodzielny Publiczny Szpital Kliniczny, Wroclaw

Institutul de Endocrinologie C.I.Parhon, Sectia clinica de endocrinologie II, Bucharest

Institutul de Endocrinologie C.I.Parhon, Sectia clinica de endocrinologie I, Bucharest

Institutul de Endocrinologie C.I.Parhon, Sectia clinica de endocrinologie VI, Bucharest

Clinical Center of Serbia, Belgrade

Clinical center of Nis, Niš

Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Italfarmaco

INDUSTRY

NCT02111044 - Phase II Study With ITF2984 in Acromegalic Patients | Biotech Hunter | Biotech Hunter